Table 2 Baseline clinical characteristics and treatment response of RA in the validation cohort
From: Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis
Variables | RA patients (n = 77) |
|---|---|
Age (years) | 55.56 ± 12.53 |
Gender (female, %) | 60 (77.92%) |
BMI (kg/m2) | 21.47 ± 5.87 |
Disease duration (months) | 93 (42–184) |
RF-positive (n, %) | 57 (74.03%) |
ACPA-positive (n, %) | 62 (80.52%) |
ACR20 responders (n, %) | 55 (71.43%) |
ACR50 responders (n, %) | 38 (49.35%) |
ACR70 responders (n, %) | 20 (25.97%) |
ACR non-responders (n, %) | 22 (28.57%) |